Open Nav

Caladrius Biosciences, Inc.

Showcase the pipeline to groups of investors and potential partners

  • Date:Thursday, October 18
  • Time:10:45 AM - 11:00 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:Caladrius Biosciences, Inc. is a development stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications. The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in a currently enrolling Phase 2 trial. CLBS14 is Caladrius’ proprietary and patent protected formulation of CD34 cells designed specifically to enhance the potency of the CD34 cells for repair and regeneration of cardiovascular tissue. Its companion product, CLBS12, is specifically formulated for intramuscular administration for the treatment of lower extremity ischemia.
  • Company Website:https://www.caladrius.com/
  • Company HQ City:Basking Ridge
  • Company HQ Country:United States
  • Company HQ State:New Jersey                 
  • Market Cap:31.8 million
  • Ticker:CLBS
  • Exchange:NASDAQ
  • CEO/Top Company Official:David J. Mazzo, PhD
  • Year Founded:2006
  • Main Therapeutic Focus:Gene/Cell Therapy
  • Lead Product in Development :CLBS03
  • Development Phase of Primary Product:Phase II
Back